Free Trial

Molecular Partners (MOLN) Competitors

Molecular Partners logo
$4.01 +0.01 (+0.23%)
Closing price 03:56 PM Eastern
Extended Trading
$3.96 -0.05 (-1.35%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MOLN vs. EOLS, ORGO, PRME, ABUS, BCYC, UPB, KURA, TSHA, TBPH, and KROS

Should you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Evolus (EOLS), Organogenesis (ORGO), Prime Medicine (PRME), Arbutus Biopharma (ABUS), Bicycle Therapeutics (BCYC), Upstream Bio (UPB), Kura Oncology (KURA), Taysha Gene Therapies (TSHA), Theravance Biopharma (TBPH), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry.

Molecular Partners vs. Its Competitors

Molecular Partners (NASDAQ:MOLN) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Molecular Partners currently has a consensus price target of $12.00, indicating a potential upside of 199.33%. Evolus has a consensus price target of $23.75, indicating a potential upside of 149.21%. Given Molecular Partners' stronger consensus rating and higher possible upside, research analysts clearly believe Molecular Partners is more favorable than Evolus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Molecular Partners
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50
Evolus
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Evolus has higher revenue and earnings than Molecular Partners. Evolus is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Partners$5.65M28.65-$61.39M-$1.92-2.09
Evolus$266.27M2.31-$50.42M-$0.89-10.71

Molecular Partners has a net margin of 0.00% compared to Evolus' net margin of -20.40%. Molecular Partners' return on equity of -42.20% beat Evolus' return on equity.

Company Net Margins Return on Equity Return on Assets
Molecular PartnersN/A -42.20% -38.12%
Evolus -20.40%-759.04%-20.14%

Molecular Partners has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Evolus has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Comparatively, 5.9% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Evolus had 2 more articles in the media than Molecular Partners. MarketBeat recorded 4 mentions for Evolus and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.94 beat Evolus' score of 0.93 indicating that Molecular Partners is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Molecular Partners
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Evolus
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Molecular Partners beats Evolus on 10 of the 17 factors compared between the two stocks.

Get Molecular Partners News Delivered to You Automatically

Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MOLN vs. The Competition

MetricMolecular PartnersMED IndustryMedical SectorNASDAQ Exchange
Market Cap$161.49M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-2.0921.0428.0720.05
Price / Sales28.65284.46448.5799.42
Price / CashN/A42.7636.2258.56
Price / Book1.008.378.665.87
Net Income-$61.39M-$55.19M$3.25B$258.55M
7 Day Performance10.59%5.89%4.20%2.23%
1 Month Performance8.64%17.63%10.82%12.76%
1 Year Performance-31.47%5.09%34.70%19.36%

Molecular Partners Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MOLN
Molecular Partners
2.5708 of 5 stars
$4.01
+0.2%
$12.00
+199.3%
-38.4%$161.49M$5.65M-2.09180News Coverage
Gap Up
EOLS
Evolus
3.7218 of 5 stars
$9.57
+3.8%
$23.75
+148.2%
-21.5%$617.04M$275.46M-10.75170Positive News
Upcoming Earnings
ORGO
Organogenesis
4.5393 of 5 stars
$4.82
+5.7%
$6.50
+34.9%
+53.2%$611.44M$458.76M-28.35950
PRME
Prime Medicine
3.8541 of 5 stars
$4.53
-0.9%
$9.25
+104.2%
-20.8%$609.27M$3.85M-2.21234Gap Down
ABUS
Arbutus Biopharma
2.2821 of 5 stars
$3.15
+0.3%
$5.50
+74.6%
-16.3%$603.31M$6.40M-7.6890
BCYC
Bicycle Therapeutics
3.8213 of 5 stars
$8.37
+0.7%
$24.22
+189.4%
-63.5%$579.66M$25.72M-2.67240
UPB
Upstream Bio
1.7838 of 5 stars
$10.75
+1.0%
$56.50
+425.6%
N/A$578.24M$2.37M0.0038News Coverage
KURA
Kura Oncology
4.495 of 5 stars
$6.67
+3.1%
$24.50
+267.3%
-68.2%$577.46M$67.99M-3.18130Positive News
TSHA
Taysha Gene Therapies
4.2565 of 5 stars
$2.63
+4.0%
$8.17
+210.5%
+15.6%$564.56M$8.33M-7.74180
TBPH
Theravance Biopharma
1.7803 of 5 stars
$11.23
-1.1%
$16.60
+47.8%
+11.3%$561.51M$65.27M-9.52110
KROS
Keros Therapeutics
2.2103 of 5 stars
$13.73
-0.4%
$30.56
+122.5%
-71.0%$557.71M$3.55M-76.28100

Related Companies and Tools


This page (NASDAQ:MOLN) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners